Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Paper describes novel in situ cancer vaccine to cure recurrent cancer
May 13th, 2004
Generex Biotechnology Corp. (GNBT) announced the publication of an invited review in Cancer Treatment Reviews. This paper, by Antigen Express scientists and collaborators, describes their preclinical data supporting a novel and patented mechanism to induce presentation of a full spectrum of antigenic epitopes by a tumor to T-helper cells of the patient. Remaining issues to initiating clinical trials with this novel therapy in otherwise poor prognosis patients are outlined. This invited paper, "Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation," by Gali...
Source: Women's Health Weekly (2004-05-13)
|
